COX-2 inhibition in clinical cancer prevention.

Colorectal cancer is an excellent model for studying cancer prevention by means of secondary (e.g., polypectomy to remove a precursor adenoma) and primary (chemoprevention) strategies. Evidence has shown that regular users of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have a reduction in risk of colorectal cancer. A possible mechanism of this benefit is decreased prostaglandin production, which is achieved through inhibition of cyclooxygenase (COX) activity, and possibly other pathways. Two isoforms of COX--COX-1 and COX-2--have been identified. COX-2 is expressed in colorectal adenomas and carcinomas, both in humans and rodents. Inhibition of COX-2 has been shown to decrease the incidence of carcinogen-induced neoplasia in rats and to lower the incidence of adenomas in murine models. Several COX-2 inhibitors, with the potential for less toxicity than that associated with traditional NSAIDs, are under development. This paper reviews potential chemoprevention of colorectal cancer using COX-2 inhibitors in patients at increased risk, e.g., patients with familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, and sporadic adenomas. Included are the rationale for use of such agents, results of a study showing a significant reduction in adenoma burden in familial adenomatous polyposis patients who received the selective COX-2 inhibitor celecoxib (Celebrex), and the design of other ongoing or planned clinical trials.

[1]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[2]  G. Harewood.  Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. , 1999, The New England journal of medicine.

[3]  A. Jarry,et al.  Interleukin 1 and interleukin 1β converting enzyme (caspase 1) expression in the human colonic epithelial barrier. Caspase 1 downregulation in colon cancer , 1999, Gut.

[4]  F. Sinicrope,et al.  Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. , 1999, Gastroenterology.

[5]  G. Geis.  Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? , 1999, Scandinavian journal of rheumatology. Supplement.

[6]  M. Mandal,et al.  Regulation of Cyclooxygenase-2 pathway by HER2 receptor , 1999, Oncogene.

[7]  M. Taketo.  Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). , 1998, Journal of the National Cancer Institute.

[8]  P. Lipsky,et al.  Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. , 1998, Arthritis and rheumatism.

[9]  J. Mathers,et al.  Diet and cancer prevention: the Concerted Action Polyp Prevention (CAPP) Studies , 1998, Proceedings of the Nutrition Society.

[10]  K. Seibert,et al.  Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. , 1998, Cancer research.

[11]  D. Alberts,et al.  Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. , 1997, Cancer research.

[12]  P. Lipsky,et al.  Outcome of specific COX-2 inhibition in rheumatoid arthritis. , 1997, The Journal of rheumatology. Supplement.

[13]  J. Morrow,et al.  Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[15]  K. Seibert,et al.  Advances in Brief Evaluation of Cyclooxygenase-2 Inhibitor for Potential Chemopreventive Properties in Colon Carcinogenesis ' , 2006 .

[16]  M. Bertagnolli,et al.  Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. , 1996, Cancer research.

[17]  P. Pasricha,et al.  The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. , 1995, Gastroenterology.

[18]  K. Schmid,et al.  Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment , 1995, Diseases of the colon and rectum.

[19]  J. Mathers,et al.  The protocol for a European double-blind trial of aspirin and resistant starch in familial adenomatous polyposis: the CAPP study. Concerted Action Polyposis Prevention. , 1995, European journal of cancer.

[20]  S Jothy,et al.  Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. , 1995, Cancer research.

[21]  A. Cats,et al.  Randomized, double-blinded, placebo-controlled intervention study with supplemental calcium in families with hereditary nonpolyposis colorectal cancer. , 1995, Journal of the National Cancer Institute.

[22]  J. Gierse,et al.  Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. , 1995, The Biochemical journal.

[23]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[24]  Y. Niv,et al.  Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. , 1994, Gastroenterology.

[25]  E. Rimm,et al.  Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professionals , 1994, Annals of Internal Medicine.

[26]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[27]  C. Williams,et al.  Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis , 1993, The British journal of surgery.

[28]  G. Kelloff,et al.  Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. , 1993, Carcinogenesis.

[29]  S. Piantadosi,et al.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.

[30]  J. Bordas,et al.  Effects of long-term sulindac therapy on colonic polyposis. , 1991, Annals of internal medicine.

[31]  M. Thun,et al.  Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.

[32]  P. Vielh,et al.  Sulindac causes regression of rectal polyps in familial adenomatous polyposis. , 1991, Gastroenterology.

[33]  S. Altschul,et al.  Identification of FAP locus genes from chromosome 5q21. , 1991, Science.

[34]  S. Shapiro,et al.  A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. , 1991, Journal of the National Cancer Institute.

[35]  L F Watson,et al.  Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988. , 2007, International journal of epidemiology.

[36]  A. Pegg,et al.  Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. , 1988, Cancer research.

[37]  W. Waddell,et al.  Sulindac for polyposis of the colon , 1983, Journal of surgical oncology.

[38]  P. McCann,et al.  Inhibition of ornithine decarboxylase with 2-difluoromethylornithine: reduced incidence of dimethylhydrazine-induced colon tumors in mice. , 1983, Cancer research.

[39]  John Calvin Reed.  Mechanisms of apoptosis avoidance in cancer. , 1999, Current opinion in oncology.

[40]  J. Vane,et al.  Mechanism of action of anti-inflammatory drugs. , 1996, Scandinavian journal of rheumatology. Supplement.

[41]  Morris Pollard,et al.  Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. , 1980, Cancer treatment reports.